Results 171 to 180 of about 133,056 (344)

Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients

open access: yesAdvanced Biomedical Research
Background: Myelodysplastic syndrome (MDS) is a clonal hematologic disorder that requires the integration of morphologic, cytogenetic, hematologic, and clinical findings for a successful diagnosis.
Parvin Khalilian   +4 more
doaj   +1 more source

Role of TLR1, TLR2 and TLR6 in the modulation of intestinal inflammation and Candida albicans elimination

open access: yesGut Pathogens, 2017
Background Toll-like receptors (TLRs) are the major pattern recognition receptors that mediate sensing of a wide range of microorganisms. TLR2 forms heterodimers with either TLR1 or TLR6, broadening its ligand diversity against pathogens.
L. Choteau   +10 more
semanticscholar   +1 more source

Synthetic Biology‐Based Engineering Living Therapeutics for Antimicrobial Application

open access: yesExploration, EarlyView.
This perspective highlights synthetic biology‐driven antibacterial strategies, focusing on three innovative approaches: engineered bacteriophages for precision bacterial targeting, reprogrammed microbes that detect quorum‐sensing signals or metabolites to release antimicrobials, and engineering mammalian cells that recognize pathogen‐associated ...
Shun Huang   +4 more
wiley   +1 more source

Biglycan : a multivalent proteoglycan providing structure and signals [PDF]

open access: yes, 2013
Research over the past few years has provided fascinating results indicating that biglycan, besides being a ubiquitous structural component of the extracellular matrix (ECM), may act as a signaling molecule.
Năstase, Mădălina-Viviana   +2 more
core  

Ontogeny of Toll-Like Receptors Tlr2 and Tlr4 in Mice [PDF]

open access: bronze, 2001
Kirsi Harju   +2 more
openalex   +1 more source

Immunomodulatory natural polysaccharide‐based nanoparticles for the treatment of neurodegenerative diseases

open access: yesIbrain, EarlyView.
Polysaccharide‐based nanoparticles offer versatile platforms for drug delivery and immune modulation in neurodegenerative diseases. This review highlights their potential in treating Alzheimer's, Parkinson's, and multiple sclerosis, focusing on targeted delivery and neuroinflammation.
Leto‐Aikaterini Tziveleka   +5 more
wiley   +1 more source

Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm

open access: yesActa Pharmaceutica Sinica B, 2015
Abdominal aortic aneurysm (AAA) is an inflammatory vascular disorder with high mortality. Accumulating evidence shows that toll-like receptor 2 (TLR2) plays a critical role in the regulation of wound-repairing process after tissue injury.
Huimin Yan   +8 more
doaj   +1 more source

Endocytosed HSP60s Use Toll-like Receptor 2 (TLR2) and TLR4 to Activate the Toll/Interleukin-1 Receptor Signaling Pathway in Innate Immune Cells [PDF]

open access: hybrid, 2001
R. Martin Vabulas   +6 more
openalex   +1 more source

TLR2−/− Mice Display Decreased Severity of Giardiasis via Enhanced Proinflammatory Cytokines Production Dependent on AKT Signal Pathway

open access: yesFrontiers in Immunology, 2017
Giardia infection is one of the most common causes of waterborne diarrheal disease in a wide array of mammalian hosts, including humans globally. Although numerous studies have indicated that adaptive immune responses are important for Giardia defense ...
Xin Li   +6 more
semanticscholar   +1 more source

CD86, the double agent: Significance of CD86 expression in B‐cell malignancies

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Bypassing the anti‐tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA‐4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an ...
Gábor Barna   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy